Clinical trial data ‘Gather’ed digitally

Exco InTouch, a provider of patient engagement and data capture solutions for clinical research and healthcare providers, has launched Gather, a product suite that offers end-to-end engagement for participants in clinical studies

Gather is designed to connect independent technology systems and can manage stakeholder engagement and in clinical trials, according to Exco InTouch.

All components of clinical trials, from patient recruitment and study design through to electronic clinical outcomes assessment (eCOA) and reporting are connected and integrated into Gather.

The system provides a two-way transfer of information between patients, site managers and study teams, while ensuring it remains within study protocols.

Companies are able to select the components suited to their trial protocols, adding and removing elements as appropriate with no disruption, according to Exco InTouch.

Tim Davis, CEO and founder of Exco InTouch, said: “We believe that the time has come for our industry to take a step back and to re-assess how we approach the use of digital technology within the clinical environment. Gather is the realisation of this vision.”

Gather can also be accessed through any internet-connected device, allowing the selection of the most appropriate device, or devices, for the study protocol, geography and patient demographic, according to Exco InTouch.

Davis said: “By combining our existing patient-centric products within one system, we have created something that is far greater than the sum of its parts.

“Gather provides enhanced engagement for all stakeholders in the clinical trial process improving efficiency, workflow and providing a logical integrated view of data generated throughout the study lifecycle.”

Davis continued: “The pharmaceutical industry is sometimes seen as slow to adapt but we expect everyone involved to quickly pick up on the immense benefits this approach brings with it – Gather will have a transformational effect on how we design, conduct and evaluate future trials.”